The biggest breakthrough of the 21st Century

| White Listing Instructions|

Dear Money Morning Reader, We've come across what could well be the biggest breakthrough in medical science in over a century. Something even bigger than penicillin or the Salk vaccine. It's a drug breakthrough that does something that's never been done before... it can actually clone itself to fight the biggest, most dreaded disease known to man. Oddly enough, it was created by a small company outside Washington D.C. Our estimates show that this could well become the most profitable drug of the century, with the potential to gross over $120 billion. The ramifications for early investors are, to put it frankly, pretty mind blowing. Our just released report is here. It's a must read. Sincerely, Mike Ward Publisher, Money Morning GO HERE TO SEE THIS BREAKTHROUGH Money Morning : You are receiving this e-mail as a part of your free subscription to The Money Morning E-Letter. Remove your email from this list: Unsubscribe To cancel by mail or for any other subscription issues, write us at: Money Morning Attn: Member Services 105 West Monument Street Baltimore, MD 21201 © 2010 Money Morning All Rights Reserved Money Morning· 105 West Monument Street · Baltimore, MD 21201 North America: 1 888 384 8339; Fax: 1 410 223 2650 International: +1 410 230 1200; Fax: +1 410 223 2650 Website: http://www.moneymorning.com Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Money Morning. 105 W. Monument Street, Baltimore MD 21201.

---